Alimera Sciences, Inc, a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone678-990-5740
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$46.97 million
Profitability
Miscellaneous
Employees124
Next Earnings Date10/29/2019 (Confirmed)
OptionableOptionable
Alimera Sciences (NASDAQ:ALIM) Frequently Asked Questions
What is Alimera Sciences' stock symbol?
Alimera Sciences trades on the NASDAQ under the ticker symbol "ALIM."
How were Alimera Sciences' earnings last quarter?
Alimera Sciences Inc (NASDAQ:ALIM) posted its earnings results on Monday, July, 29th. The biopharmaceutical company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.04) by $0.03. The biopharmaceutical company earned $10.86 million during the quarter, compared to analysts' expectations of $12.97 million. View Alimera Sciences' Earnings History.
When is Alimera Sciences' next earnings date?
How can I listen to Alimera Sciences' earnings call?
Alimera Sciences will be holding an earnings conference call on Tuesday, October 29th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What guidance has Alimera Sciences issued on next quarter's earnings?
Alimera Sciences issued an update on its third quarter 2019 earnings guidance on Wednesday, October, 2nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $12.8 million, compared to the consensus revenue estimate of $12.87 million.
What price target have analysts set for ALIM?
3 brokerages have issued 12 month target prices for Alimera Sciences' stock. Their predictions range from $2.00 to $3.00. On average, they expect Alimera Sciences' stock price to reach $2.33 in the next year. This suggests a possible upside of 566.7% from the stock's current price. View Analyst Price Targets for Alimera Sciences.
What is the consensus analysts' recommendation for Alimera Sciences?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alimera Sciences in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alimera Sciences.
Has Alimera Sciences been receiving favorable news coverage?
Media headlines about ALIM stock have trended somewhat positive this week, InfoTrie reports. InfoTrie rates the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Alimera Sciences earned a daily sentiment score of 0.8 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Alimera Sciences.
Are investors shorting Alimera Sciences?
Alimera Sciences saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 313,700 shares, an increase of 123.1% from the August 30th total of 140,600 shares. Based on an average daily volume of 305,100 shares, the short-interest ratio is currently 1.0 days. Approximately 0.5% of the company's stock are short sold. View Alimera Sciences' Current Options Chain.
Who are some of Alimera Sciences' key competitors?
Some companies that are related to Alimera Sciences include Processa Pharmaceuticals (PCSA), Chembio Diagnostics (CEMI), Millendo Therapeutics (MLND), VBI Vaccines (VBIV), CELYAD SA/ADR (CYAD), Immunic (IMUX), Fortress Biotech (FBIO), Avenue Therapeutics (ATXI), Ovid Therapeutics (OVID), Chimerix (CMRX), Aduro BioTech (ADRO), Trevena (TRVN), BioXcel Therapeutics (BTAI), NeuBase Therapeutics (NBSE) and Galmed Pharmaceuticals (GLMD).
What other stocks do shareholders of Alimera Sciences own?
Who are Alimera Sciences' key executives?
Alimera Sciences' management team includes the folowing people:
- Mr. Charles Daniel Myers, Non-Exec. Chairman & Consultant (Age 65)
- Mr. Richard S. Eiswirth Jr., Pres, CEO & Director (Age 51)
- Dr. Kenneth Green, Consultant (Age 61)
- Mr. David R. Holland, Co-Founder, Chief Marketing Officer and Sr. VP of Corp. Communications & Managed Markets (Age 55)
- Mr. J. Philip Jones, Chief Financial Officer (Age 55)
How do I buy shares of Alimera Sciences?
Shares of ALIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Alimera Sciences' stock price today?
One share of ALIM stock can currently be purchased for approximately $0.35.
How big of a company is Alimera Sciences?
What is Alimera Sciences' official website?
How can I contact Alimera Sciences?
Alimera Sciences' mailing address is 6120 WINDWARD PARKWAY STE 290, ALPHARETTA GA, 30005. The biopharmaceutical company can be reached via phone at 678-990-5740 or via email at [email protected]
MarketBeat Community Rating for Alimera Sciences (NASDAQ ALIM)
MarketBeat's community ratings are surveys of what our community members think about Alimera Sciences and other stocks. Vote "Outperform" if you believe ALIM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALIM will underperform the S&P 500 over the long term. You may vote once every thirty days.
